PL4097091T3 - Postacie stałe mawakamtenu i sposób ich wytwarzania - Google Patents
Postacie stałe mawakamtenu i sposób ich wytwarzaniaInfo
- Publication number
- PL4097091T3 PL4097091T3 PL21706793.3T PL21706793T PL4097091T3 PL 4097091 T3 PL4097091 T3 PL 4097091T3 PL 21706793 T PL21706793 T PL 21706793T PL 4097091 T3 PL4097091 T3 PL 4097091T3
- Authority
- PL
- Poland
- Prior art keywords
- mavacamten
- preparation
- solid state
- state forms
- forms
- Prior art date
Links
- RLCLASQCAPXVLM-NSHDSACASA-N CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O Chemical compound CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O RLCLASQCAPXVLM-NSHDSACASA-N 0.000 title 1
- 229940069673 mavacamten Drugs 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966665P | 2020-01-28 | 2020-01-28 | |
| US202062980503P | 2020-02-24 | 2020-02-24 | |
| US202063008009P | 2020-04-10 | 2020-04-10 | |
| PCT/US2021/015358 WO2021154904A1 (en) | 2020-01-28 | 2021-01-28 | Solid state forms of mavacamten and process for preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4097091T3 true PL4097091T3 (pl) | 2025-01-27 |
Family
ID=74669560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21706793.3T PL4097091T3 (pl) | 2020-01-28 | 2021-01-28 | Postacie stałe mawakamtenu i sposób ich wytwarzania |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20230057197A1 (pl) |
| EP (2) | EP4480538A3 (pl) |
| JP (1) | JP7795063B2 (pl) |
| CN (1) | CN115515941A (pl) |
| AU (1) | AU2021213748A1 (pl) |
| CA (1) | CA3165995A1 (pl) |
| ES (1) | ES3005093T3 (pl) |
| HR (1) | HRP20241597T1 (pl) |
| HU (1) | HUE069154T2 (pl) |
| IL (1) | IL294501A (pl) |
| PL (1) | PL4097091T3 (pl) |
| SI (1) | SI4097091T1 (pl) |
| WO (1) | WO2021154904A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7795063B2 (ja) | 2020-01-28 | 2026-01-07 | アッシア・ケミカル・インダストリーズ・リミテッド | マバカムテンの固体形態及びその調製のための方法 |
| CN112939876A (zh) * | 2021-03-10 | 2021-06-11 | 杭州科巢生物科技有限公司 | Mavacamten的晶型I及其制备方法 |
| WO2022189599A1 (en) * | 2021-03-12 | 2022-09-15 | Sandoz Ag | Crystalline forms of mavacamten for the treatment of hcm |
| CA3248508A1 (en) | 2022-04-13 | 2023-10-19 | Assia Chemical Industries Ltd. | SOLID STATE FORMS OF MAVACAMTEN AND THEIR PREPARATION METHOD |
| WO2024134368A1 (en) * | 2022-12-23 | 2024-06-27 | Aurobindo Pharma Limited | Solid state form of mavacamten |
| WO2025046606A1 (en) | 2023-08-26 | 2025-03-06 | Micro Labs Limited | Granules of mavacamten for oral administration |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000071T1 (it) * | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| SI3661514T1 (sl) * | 2017-08-04 | 2026-01-30 | MyoKardia, Inc. | Mavacamten za uporabo pri zdravljenju hipertrofične kardiomiopatije |
| CN114945372A (zh) * | 2019-11-10 | 2022-08-26 | 迈奥卡迪亚公司 | 用肌球蛋白调节剂的治疗方法 |
| JP7795063B2 (ja) | 2020-01-28 | 2026-01-07 | アッシア・ケミカル・インダストリーズ・リミテッド | マバカムテンの固体形態及びその調製のための方法 |
| CA3206864A1 (en) | 2021-02-01 | 2022-08-04 | Divya Jyothi Kallem | Process for preparation of mavacamten and solid state forms thereof |
| CN112939876A (zh) | 2021-03-10 | 2021-06-11 | 杭州科巢生物科技有限公司 | Mavacamten的晶型I及其制备方法 |
| WO2022189599A1 (en) | 2021-03-12 | 2022-09-15 | Sandoz Ag | Crystalline forms of mavacamten for the treatment of hcm |
| CA3248508A1 (en) | 2022-04-13 | 2023-10-19 | Assia Chemical Industries Ltd. | SOLID STATE FORMS OF MAVACAMTEN AND THEIR PREPARATION METHOD |
-
2021
- 2021-01-28 JP JP2022546095A patent/JP7795063B2/ja active Active
- 2021-01-28 IL IL294501A patent/IL294501A/en unknown
- 2021-01-28 WO PCT/US2021/015358 patent/WO2021154904A1/en not_active Ceased
- 2021-01-28 US US17/792,754 patent/US20230057197A1/en not_active Abandoned
- 2021-01-28 EP EP24197956.6A patent/EP4480538A3/en active Pending
- 2021-01-28 PL PL21706793.3T patent/PL4097091T3/pl unknown
- 2021-01-28 ES ES21706793T patent/ES3005093T3/es active Active
- 2021-01-28 SI SI202130229T patent/SI4097091T1/sl unknown
- 2021-01-28 CN CN202180025380.2A patent/CN115515941A/zh active Pending
- 2021-01-28 CA CA3165995A patent/CA3165995A1/en active Pending
- 2021-01-28 AU AU2021213748A patent/AU2021213748A1/en active Pending
- 2021-01-28 HR HRP20241597TT patent/HRP20241597T1/hr unknown
- 2021-01-28 HU HUE21706793A patent/HUE069154T2/hu unknown
- 2021-01-28 EP EP21706793.3A patent/EP4097091B1/en active Active
-
2024
- 2024-03-20 US US18/610,777 patent/US12258320B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230057197A1 (en) | 2023-02-23 |
| CN115515941A (zh) | 2022-12-23 |
| EP4097091B1 (en) | 2024-09-18 |
| HUE069154T2 (hu) | 2025-02-28 |
| HRP20241597T1 (hr) | 2025-01-31 |
| US20240228442A1 (en) | 2024-07-11 |
| EP4480538A2 (en) | 2024-12-25 |
| EP4097091A1 (en) | 2022-12-07 |
| WO2021154904A1 (en) | 2021-08-05 |
| EP4480538A3 (en) | 2025-04-02 |
| CA3165995A1 (en) | 2021-08-05 |
| AU2021213748A1 (en) | 2022-08-25 |
| SI4097091T1 (sl) | 2025-05-30 |
| JP2023512518A (ja) | 2023-03-27 |
| IL294501A (en) | 2022-09-01 |
| US12258320B2 (en) | 2025-03-25 |
| JP7795063B2 (ja) | 2026-01-07 |
| ES3005093T3 (en) | 2025-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE069154T2 (hu) | A mavakamten szilárd állapotú formái és eljárás elõállításukra | |
| IL321258A (en) | Crystalline forms of zipleratinib and process for their preparation | |
| EP4041198A4 (en) | SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF | |
| IL289453B2 (en) | Process for preparing ridinilazole and its crystalline forms | |
| EP4228629A4 (en) | PROCESS FOR PREPARING TAFAMIDIS AND SALTS THEREOF | |
| EP4096662A4 (en) | METHOD FOR PRODUCING LASMIDITAN | |
| IL320431A (en) | Crystalline forms of zibagen hydrochloride and process for their preparation | |
| HUP2100414A1 (hu) | Eljárás bioadszorbens anyag elõállítására | |
| HUE067201T2 (hu) | Eljárás és intermedier oxetan-2-il-metánamin elõállítására | |
| IL283201A (en) | Process and compounds for preparation of cannabinoids | |
| GB202012765D0 (en) | Compositions and methods of production thereof | |
| SG11202104657RA (en) | Formulation of contrast media and process of preparation thereof | |
| IL320719A (en) | Solid forms of blomosodil and processes for obtaining blomosodil | |
| HUP2300098A1 (hu) | Eljárás upadacitinib elõállítására | |
| SMT202200166T1 (it) | Polimorfo del sodio neridronato e relativo procedimento di preparazione | |
| CA3306788A1 (en) | Solid state forms of linerixibat and process for preparation thereof | |
| CA3299035A1 (en) | Solid state forms of buntanetap and process for preparation thereof | |
| CA3276267A1 (en) | Solid state forms of zipalertinib and process for preparation thereof | |
| HUP2100077A1 (hu) | Eljárás avapritinib és intermedierek elõállítására | |
| CA3310843A1 (en) | Solid state forms of zipalertinib hydrochloride and process for preparation thereof | |
| CA3273281A1 (en) | Solid state forms of belumosudil and processes for preparation thereof | |
| CA3310965A1 (en) | Process for preparation of milvexian and solid-state forms thereof | |
| CA3309885A1 (en) | Solid state forms of deutivacaftor and process thereof | |
| CA3283859A1 (en) | Solid state forms of delgocitinib and process thereof | |
| GB2599284B (en) | Edible paste and composition and method of preparation |